Equities

Suven Pharmaceuticals Ltd

SUVENPHAR:NSI

Suven Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,287.70
  • Today's Change7.70 / 0.60%
  • Shares traded74.55k
  • 1 Year change+127.55%
  • Beta1.6610
Data delayed at least 15 minutes, as of Nov 08 2024 10:02 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments8,2344,8595,279
Total Receivables, Net2,0081,8492,930
Total Inventory2,3313,3063,000
Prepaid expenses498664
Other current assets, total10115.92
Total current assets12,63210,11011,279
Property, plant & equipment, net7,8687,6625,620
Goodwill, net603----
Intangibles, net1762222
Long term investments1,4001,1711,171
Note receivable - long term0.0833131
Other long term assets2259--
Total assets22,54119,65718,296
LIABILITIES
Accounts payable4246521,059
Accrued expenses------
Notes payable/short-term debt0446471
Current portion long-term debt/capital leases438205211
Other current liabilities, total208285362
Total current liabilities1,0691,5882,103
Total long term debt21253289
Total debt650703971
Deferred income tax648582543
Minority interest------
Other liabilities, total1058389
Total liabilities2,0342,3063,024
SHAREHOLDERS EQUITY
Common stock255255255
Additional paid-in capital1,0961,0961,096
Retained earnings (accumulated deficit)18,91415,89413,857
Treasury stock - common------
Unrealized gain (loss)237107--
Other equity, total5.26--65
Total equity20,50717,35215,272
Total liabilities & shareholders' equity22,54119,65718,296
Total common shares outstanding255255255
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.